Asparaginase Hypersensitivity and Silent Inactivation in ALL - prIME Oncology
Virtual Journal Club
Virtual Journal Club

Asparaginase Hypersensitivity and Silent Inactivation in ALL

Identification and Management

Not a member of My prIME? Join now for instant access.

Stay up-to-date on best practices in managing asparaginase treatment in patients with acute lymphoblastic leukemia (ALL). Drs Patrick Brown, MD, and Stacy Cooper, MD, discuss, in depth, a recent consensus publication focusing on the identification and management of hypersensitivity reactions in pediatric patients receiving asparaginase treatment. Watch this CME-certified activity for expert perspectives in patient management.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credit

Release Date

Release Date

Nov 30, 2017

Expiration Date

Dec 2, 2018

  • Patrick Brown, MDJohns Hopkins University School of Medicine
    Baltimore, Maryland, United States
  • Stacy Cooper, MDJohns Hopkins University School of Medicine
    Baltimore, Maryland, United States

This educational activity is designed to meet the needs of hematologists and other healthcare professionals involved in the treatment of patients with ALL.

After successful completion of this educational activity, participants should be able to:

  • Discuss best practices for assessing asparaginase activity in patients with ALL
  • Develop management strategies to treat patients with ALL who develop clinical allergic reactions on asparaginase therapy
  • Implement recommended best practices to manage patients with ALL who develop “silent inactivation” of asparaginase activity

This educational activity is supported by a grant from Jazz Pharmaceuticals.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Asparaginase Hypersensitivity and Silent Inactivation in ALL - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Brown has disclosed that he has membership on advisory committees or review panels for Novartis Oncology and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cooper has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content manager) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.